What is Skin Cancer?

Skin cancer is the most common malignancy in humans globally. It arises from abnormal growth of skin cells, typically on sun-exposed areas, though non-melanoma skin cancers can develop anywhere on the body. Three main types account for over 99% of cases: basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. While BCC and SCC grow slowly and rarely spread beyond the skin, melanoma is more aggressive and carries higher risk of metastasis.

In India, skin cancer remains less prevalent than in Western countries due to higher melanin content in skin; however, incidence is rising 2–3% annually. Acral melanoma (on palms, soles, nail beds) is disproportionately common in Indian and other non-Caucasian populations. Squamous cell carcinoma arising from chronic wounds, burn scars, and long-standing ulcers is a particular concern in resource-limited settings. Early detection through routine skin checks and prompt treatment at specialized centers yields excellent outcomes for BCC and SCC, and significantly improves prognosis for melanoma.

Modern dermatologic oncology combines precision surgery (Mohs micrographic surgery, wide local excision), immunotherapy, targeted molecular therapy, and adjuvant protocols tailored to stage and histology. HealOnco’s skin cancer program integrates expert surgical oncology, dermatologic pathology review, and systemic therapy for advanced disease, ensuring comprehensive care in a day-care setting where feasible.

Types of Skin Cancer

Signs and Symptoms of Skin Cancer

1. ABCDE Rule (Melanoma): Asymmetry (one half unlike other), Border irregularity, Color variation (multiple colors in one lesion), Diameter >6 mm (pencil eraser size), Evolving (changing in size, shape, or color over weeks to months)
2. Basal Cell Carcinoma: Pearly, translucent papule or nodule with rolled border and central ulceration; may bleed or crust; often on face, ears, or neck; slow growth over months to years
3. Squamous Cell Carcinoma: Scaly, erythematous patch or plaque; nodule or horn-like growth; may ulcerate; often on sun-exposed areas; bleeding or non-healing wound
4. Merkel Cell Carcinoma: Firm, painless, rapidly enlarging nodule; often flesh-colored or reddish; typically on face, scalp, or extremities; rapid growth over weeks
5. Acral Melanoma (Indian populations): Pigmented lesion on palm, sole, or nail bed; may present as dark streak in nail (subungual melanoma); often diagnosed at thicker stage due to diagnostic delay
6. Warning Signs—Consult dermatologist: Any new or changing mole, lesion that itches or bleeds, non-healing wound, irregular borders, multiple colors, rapid growth, family history of melanoma

The ABCDE rule has ~88% sensitivity for melanoma; however, 10–15% of melanomas may not fit all criteria. Any changing or atypical lesion warrants professional evaluation.

Risk Factors for Skin Cancer

Risk varies by skin type, geographic location, and cumulative exposure history. Understanding personal risk factors enables early detection and appropriate screening protocols.

Sources: NCCN Clinical Practice Guidelines, American Academy of Dermatology, WHO/IARC, Indian Council of Medical Research (ICMR)

How Skin Cancer is Diagnosed

Early diagnosis is essential. Most skin cancers are detected on clinical examination and confirmed via tissue biopsy. Advanced imaging (ultrasound, CT, MRI, PET) used for staging melanoma and high-risk disease.

Skin Cancer Staging (AJCC 8th Edition (2017) and 9th Edition updates)

Staging uses TNM (Tumor, Node, Metastasis) classification. Non-melanoma skin cancers (BCC, SCC) grouped as low-risk and high-risk. Melanoma staged I–IV based on Breslow thickness, mitotic rate, ulceration, and nodal/distant involvement.

AJCC 9th Edition (2022) updates include refined T-stage criteria for melanoma (addition of tumor mitotic rate, microsatellitosis, and revised T1 substaging). Breslow thickness remains cornerstone of stage assignment. Sentinel lymph node status (N-stage) is critical prognostic factor not visible on imaging. Adjuvant and systemic therapy recommendations evolve; consult multidisciplinary team for latest protocols.

Treatment Options for Skin Cancer

Surgical Excision

Surgical removal with adequate margins is the primary and often curative treatment for localized skin cancers. Wide local excision (WLE) involves removing the lesion and surrounding normal-appearing skin; margin width depends on tumor thickness, location, and histologic subtype. For BCC and SCC, margins of 4–10 mm are standard. For melanoma, margins range from 1–2 cm depending on Breslow thickness and anatomic site (excision of <1 cm margin acceptable for very thin tumors).

Mohs micrographic surgery (MMS) is a tissue-sparing technique in which the surgeon acts as pathologist, examining 100% of surgical margins in real-time during the procedure. Highest cure rates (98%+) for BCC and SCC, particularly for recurrent tumors, lesions on face/eyelids, and those with aggressive histology. Allows maximum preservation of healthy tissue; preferred on cosmetically sensitive areas. Limited role for melanoma outside specialized centers, though increasingly used by trained Mohs surgeons for melanoma margins. More time-intensive and technically demanding than standard WLE; requires trained operator.

• Wide local excision (WLE): standard for most BCC, SCC, melanoma
• Mohs micrographic surgery (MMS): preferred for high-risk BCC/SCC, recurrent lesions, face/eyelid location
• Sentinel lymph node biopsy (SLNB): for melanoma Breslow ≥0.8 mm, high-risk SCC/MCC
• Complete lymph node dissection (CLND): if SLNB positive or clinically apparent nodal disease

Radiation Therapy

External beam radiation therapy (EBRT) used as adjuvant therapy for high-risk features (perineural invasion, positive margins, node involvement) or as primary therapy for inoperable lesions. Common regimens: 45–60 Gy in 15–25 fractions delivered over 3–5 weeks. Benefits include tumor cell kill and potential immunogenic effects. Toxicities include acute dermatitis, late fibrosis, pigmentation changes, and increased risk of secondary malignancy in long-term survivors.

Brachytherapy (radioactive implants) occasionally used for small, localized BCC or SCC, particularly on eyelids or in recurrent tumors. Delivers high dose to tumor with rapid dose fall-off, sparing surrounding tissue. Less widely available than EBRT.

• External beam radiation therapy (EBRT): adjuvant for perineural invasion, close/positive margins, nodal disease; primary for inoperable lesions
• Brachytherapy: for select small BCC/SCC, particularly eyelid location

Topical Therapies (BCC/SCC only)

Indicated for very superficial BCC (e.g., superficial BCC <5 mm) or SCC in situ (Bowen disease). Not effective for invasive or thick lesions. Options include 5-fluorouracil (5-FU) cream applied daily for 2–4 weeks (common regimen: 5% cream once daily for 2–6 weeks), causing inflammation followed by healing. Imiquimod (Toll-like receptor agonist) applied 3–5 times weekly for 6–12 weeks; stronger immune activation, higher recurrence rates than 5-FU but better cosmesis. Diclofenac with hyaluronic acid penetration enhancer (3% gel) approved for actinic keratoses (precursor lesions); limited data for frank SCC.

Advantages: non-invasive, good cosmetic outcome, avoids surgery in select cases. Disadvantages: lower cure rates than surgical excision (80–90% vs. 95%+), difficult to apply to irregular surfaces, longer treatment course, unknown efficacy for deep lesions.

• 5-fluorouracil (5-FU) cream 5%: for superficial BCC, SCC in situ; once daily 2–6 weeks
• Imiquimod cream 5%: for superficial BCC, SCC in situ; 3–5 times weekly for 6–12 weeks
• Diclofenac 3% gel with hyaluronic acid: for actinic keratosis and superficial SCC in situ

Immunotherapy (Advanced SCC, Melanoma)

Checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 have revolutionized treatment of advanced SCC and melanoma. PD-1 inhibitors (pembrolizumab, nivolumab) approved for melanoma and advanced cutaneous SCC. Response rates: 40–60% for advanced melanoma, 50% for advanced SCC (cemiplimab). CTLA-4 inhibitor ipilimumab used in combination with nivolumab for advanced melanoma (higher response ~60%, increased toxicity). Adjuvant checkpoint inhibitor (pembrolizumab, nivolumab) for stage IB–III melanoma reduces recurrence-free and overall survival; recommended duration 1 year.

Key mechanism: antibody blocks immune checkpoint, releasing brake on T cells to attack cancer. Toxicity profile includes immune-related adverse events (irAE): fatigue, diarrhea, hepatitis, colitis, pneumonitis, endocrinopathy (thyroiditis, adrenalitis), rash. Severe irAE (grade 3–4) occur in ~10–20% with single-agent PD-1 inhibitor, 30–40% with combination ipilimumab+nivolumab. Management: steroids, immunosuppression, dose delay or discontinuation if severe.

• Pembrolizumab (Keytruda): PD-1 inhibitor; 200 mg IV every 3 weeks; adjuvant stage IB–III melanoma, advanced melanoma/SCC
• Nivolumab (Opdivo): PD-1 inhibitor; 240–480 mg IV every 2–4 weeks; adjuvant stage IB–III melanoma, advanced melanoma/SCC
• Ipilimumab (Yervoy): CTLA-4 inhibitor; 3 mg/kg IV every 3 weeks × 4; combination with nivolumab for advanced melanoma
• Cemiplimab (Libtayo): PD-1 inhibitor; 350 mg IV every 3 weeks; advanced cutaneous SCC (FDA-approved 2018)
• Avelumab (Bavencio): PD-L1 inhibitor; 10 mg/kg IV every 2 weeks; advanced Merkel cell carcinoma

Targeted Therapy (BRAF-Mutant Melanoma)

BRAF V600E mutation present in ~40–50% of cutaneous melanoma. BRAF inhibitors (vemurafenib, dabrafenib) block mutant BRAF kinase; often combined with MEK inhibitors (cobimetinib, trametinib) to prevent resistance. Response rates: 60–70% for BRAF+MEK vs. 40–50% for BRAF alone; median progression-free survival ~9–10 months (BRAF+MEK) vs. 5–6 months (BRAF alone). Side effects: photosensitivity (vemurafenib), hand-foot skin reaction (dabrafenib), arthralgias, fever. Secondary cutaneous squamous cell carcinomas occur in ~25% of BRAF-inhibitor treated patients (thought related to paradoxical RAF activation in wild-type BRAF cells); close surveillance required.

Indications: BRAF+ advanced (stage III unresectable or IV) melanoma. Adjuvant BRAF+MEK considered for stage II–III BRAF+ melanoma in select high-risk patients. Less effective than checkpoint inhibitors in some recent trials but faster initial response; combined or sequential strategies increasingly employed. Acral and mucosal melanomas: BRAF V600E less common; c-KIT and NRAS mutations more prevalent; limited targeted options available.

• Vemurafenib (Zelboraf): BRAF inhibitor; 960 mg PO twice daily; often combined with cobimetinib
• Cobimetinib (Cotellic): MEK inhibitor; 60 mg PO daily; combined with vemurafenib
• Dabrafenib (Tafinlar): BRAF inhibitor; 150 mg PO twice daily; often combined with trametinib
• Trametinib (Mekinist): MEK inhibitor; 2 mg PO daily; combined with dabrafenib
• c-KIT inhibitors (e.g., imatinib, nilotinib): for rare c-KIT-mutant melanomas (acral, mucosal); limited evidence

Chemotherapy

Traditional chemotherapy less commonly used for skin cancer in era of immunotherapy and targeted therapy. Still employed for metastatic melanoma in patients ineligible for checkpoint inhibitors or with rapidly progressive disease. Commonly used regimen: dacarbazine (DTIC) 1000 mg/m² IV every 3 weeks; response rate ~15–20%, median OS ~10 months. Alternative: temozolomide (oral analog of DTIC) 150–200 mg/m² daily × 5 days every 4 weeks; better CNS penetration, useful for brain metastases.

For advanced Merkel cell carcinoma: combination chemotherapy (carboplatin AUC 5 + etoposide 100 mg/m² daily × 5) every 3 weeks × 4–6 cycles; response rates 60–70%. Preferred upfront for MCPyV-negative or rapidly progressive disease. Toxicity: myelosuppression, neuropathy, nausea.

• Dacarbazine (DTIC): 1000 mg/m² IV every 3 weeks; metastatic melanoma
• Temozolomide: 150–200 mg/m² daily × 5 days every 4 weeks; metastatic melanoma with CNS involvement
• Carboplatin + Etoposide: for metastatic Merkel cell carcinoma

Supportive and Palliative Care

Essential for advanced-stage disease and end-of-life care. Includes pain management (neuropathic pain common with targeted/immunotherapy), management of immune-related adverse events, nutritional support, and psychosocial counseling. Palliative radiotherapy for symptomatic metastases (bone, brain) provides symptom relief and improves quality of life. Participation in clinical trials may offer access to novel agents (e.g., BiTE antibodies, next-generation checkpoint inhibitors, oncolytic viruses).

India-specific: Access to supportive care medications (opioids, antiemetics, corticosteroids) varies by state. Generic immunotherapy and targeted agents increasingly available at lower cost than brand names. Palliative care infrastructure developing but still limited outside major cancer centers. HealOnco integrates symptom management, side-effect counseling, and quality-of-life support throughout treatment journey.

• Morphine, tramadol: for pain management
• Ondansetron, metoclopramide: antiemetics
• Prednisone, methylprednisolone: for immune-related adverse event management
• Clinical trial enrollment: access to novel immunotherapies, tyrosine kinase inhibitors

Why Adjuvant (Additional) Therapy?

Adjuvant therapy—systemic treatment given after surgery to eliminate micrometastatic disease—improves recurrence-free survival and overall survival for intermediate- and high-risk skin cancers. Even after complete surgical removal, microscopic tumor cells may persist in bloodstream, lymph nodes, or distant organs.

For melanoma stage IB–III, adjuvant checkpoint inhibitor (pembrolizumab, nivolumab) reduces recurrence-free survival hazard by ~35% and overall survival hazard by ~20% compared to observation. For BRAF+ melanoma, adjuvant BRAF+MEK shows similar benefit. Duration: 1 year. Toxicity is manageable with appropriate monitoring.

For high-risk SCC (perineural invasion, poor differentiation, immunocompromised host, extent of disease), adjuvant radiation and/or systemic therapy being evaluated in ongoing trials. Checkpoint inhibitors increasingly used off-label for high-risk metastatic or node-positive SCC based on emerging data.

In India, adjuvant therapy decisions balanced against cost, access to specialized oncology care, treatment tolerance, and patient preference. HealOnco counsels patients on recurrence risk, expected benefit of adjuvant therapy, and realistic toxicity profile to enable informed shared decision-making.

A Day at HealOnco: Skin Cancer Consultation and Treatment

Cost of Skin Cancer Treatment in India

Treatment costs vary by tumor stage, modality, center location, and whether government or private. Estimates below are typical in metropolitan areas (Delhi, Mumbai, Bangalore) as of 2026. Government facilities significantly cheaper; private centers command premium. Insurance coverage varies by plan.

Costs exclude travel, accommodation, lost wages. Insurance coverage varies: government schemes (PMJAY) cover some procedures at government facilities; private insurance requires pre-authorization and may exclude pre-existing conditions. Generic checkpoint inhibitors and targeted agents (manufactured by Indian pharma companies) significantly cheaper than brand names; efficacy equivalent. Immunotherapy and targeted therapy costs remain prohibitive for many; government hospital availability improving. State-level variations exist: Tamil Nadu, Karnataka offer better infrastructure than rural regions. Daycure procedures minimize hospitalization costs vs. traditional inpatient approaches.

Our Skin Cancer Specialists

Our Centres

Modern vs. Traditional Approaches to Skin Cancer

Pros and Cons of Treatment Options

Mohs Micrographic Surgery: Pros—highest cure rate (>98%), maximum tissue preservation, real-time feedback, single-day procedure. Cons—requires trained surgeon (limited availability in India), longer procedure time, higher upfront cost, not suitable for thick/nodular tumors.

Wide Local Excision: Pros—standard of care, widely available, simpler than Mohs, good cure rates (95%+) for low-risk lesions. Cons—may require wider margins than Mohs, potential for unnecessary tissue removal, higher recurrence (5–10%) if margins inadequate.

Radiation Therapy: Pros—non-invasive, useful for inoperable lesions or extensive disease, good for perineural invasion. Cons—late fibrosis, secondary malignancy risk (1–2% lifetime), multiple visits required, contraindicated in pregnancy, may affect cosmesis.

Topical Therapies (5-FU, Imiquimod): Pros—non-invasive, good cosmetic outcome for superficial lesions, low cost. Cons—lower cure rates (80–90%), prolonged treatment (weeks–months), uncertain efficacy for deep lesions, inflammatory side effects, patient compliance variable.

Checkpoint Inhibitor Immunotherapy: Pros—high response rates (40–60% advanced melanoma, 50% advanced SCC), improved OS, effective for unresectable/metastatic disease, well-tolerated in most patients. Cons—immune-related adverse events (10–40% grade 3–4 depending on regimen), expensive upfront, requires specialty monitoring, not all patients respond.

BRAF+MEK Targeted Therapy: Pros—rapid response (weeks), oral administration convenient, effective for BRAF+ advanced melanoma, no immunosuppression risk. Cons—photosensitivity, hand-foot skin reaction, paradoxical secondary cutaneous SCC (25%), shorter PFS than checkpoint inhibitors in some studies, requires BRAF testing.

Chemotherapy (Dacarbazine, Temozolomide): Pros—widely available, established regimens, some CNS penetration (temozolomide). Cons—low response rates (15–20%), significant myelosuppression and GI toxicity, median OS remains poor (~10 months), largely superseded by immunotherapy.

Combination Ipilimumab+Nivolumab: Pros—highest response rates (~60%) for advanced melanoma, can achieve durable responses/cures. Cons—significant immune-related adverse events (30–40% grade 3–4), requires intensive monitoring, very expensive, not all patients tolerate.

Surgical Lymph Node Dissection (CLND) vs. Observation: Pros (CLND)—complete nodal staging, potential therapeutic benefit if involved. Cons—morbidity (lymphedema 10–40%, sensory loss, infection), recurrence rates similar to observation in recent trials (MSLT-II). Current trend: observation with ultrasound surveillance; delayed CLND if recurrence.

Adjuvant Therapy Intensity: Pros (high-dose)—greater recurrence/death risk reduction in stage II–III melanoma. Cons—increased immune-related adverse events, treatment burden, cost. Risk-benefit discussion essential based on individual stage, risk factors, comorbidities.

Clinical Trial Enrollment: Pros—access to novel agents, potential survival benefit, close monitoring, costs often covered. Cons—may randomize to placebo/standard arm, unpredictable efficacy, travel burden, additional toxicity unknown, strict eligibility criteria.

Palliative Approach (Metastatic Disease): Pros—reduces treatment burden, prioritizes symptom relief and quality of life, lower toxicity. Cons—foregoes potential curative intent, survival advantage lost with systemic therapy, patient/family emotional impact.

Side Effects and How HealOnco Manages Them

Read the full side effects guide for Skin Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Skin Cancer Treatment in Top Cities

Skin Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. Sommer LL, Shinkai K. Melanoma and Non-Melanoma Skin Cancers. Cold Spring Harb Perspect Med. 2021. doi:10.1101/cshperspect.a040303 pubmed.ncbi.nlm.nih.gov
2. Linton KL, Shaikh L, Ruiz ES, et al. Acral lentiginous melanoma: epidemiology, biology, and outcomes. J Natl Cancer Inst. 2016; 108(9):djw166. pubmed.ncbi.nlm.nih.gov
3. Naeyaert JM, Brochez L. Epidemiology and risk factors of melanoma. In: Textbook of Melanoma. London: Informa Healthcare; 2012. www.routledge.com
4. Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Eur J Cancer. 2020; 126:159-177. pubmed.ncbi.nlm.nih.gov
5. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Melanoma and Cutaneous Malignancies. Version 3.2025. www.nccn.org
6. Amin MB, Edge SB, et al. (Editors). AJCC Cancer Staging Manual. 9th Edition. New York: Springer; 2020. www.springer.com
7. Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-naive advanced Merkel cell carcinoma: a randomized, phase 2 trial. Nat Med. 2018; 24(3):310-316. pubmed.ncbi.nlm.nih.gov
8. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16):1535-1546. pubmed.ncbi.nlm.nih.gov
9. Weber JS, Carlino MS, Khatri A, et al. Individual Patient Data Meta-analysis of Adjuvant Pembrolizumab in Melanoma. N Engl J Med. 2020; 383(19):1815-1826. pubmed.ncbi.nlm.nih.gov
10. Stratigos AJ, Mandala M, Chiarion-Sileni V. European Organisation for Research and Treatment of Cancer. Updated evidence-based guidelines for melanoma surveillance. Eur J Cancer. 2020; 131:1-19. pubmed.ncbi.nlm.nih.gov
11. Indian Council of Medical Research (ICMR). Global Adult Tobacco Survey: India Report. New Delhi: Ministry of Health & Family Welfare; 2016. www.icmr.gov.in
12. World Health Organization (WHO) International Agency for Research on Cancer (IARC). Global Cancer Observatory: Skin Cancer Incidence & Mortality by Country. 2024. www.iarc.who.int